Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Cancer. 2011 Dec 5;118(14):3654–3665. doi: 10.1002/cncr.26667

Table 1.

Patient, tumor and treatment characteristics.

All Patients (n=136) Grade 0-1 RP (n=96) ≥Grade 2 RP (n=40) ≥Grade 3 RP (n=19)

Patient Characteristics

Median Age (range) 66.7 (37.2-85.2) 66.8 (37.2-85.3) 61.4 (48.0-83.7) 63.9 (51.2-83.4)

Male 67 (49.3%) 41 (42.7%) 26 (65.0%) 15 (79.0%)
Female 69 (50.7%) 55 (57.3%) 14 (35.0%) 4 (21.0%)

ECOG PS
 0 62 (45.6%) 45 (46.9%) 17 (42.5%) 7 (36.8%)
 1 67 (49.3%) 49 (51.0%) 18 (45.0%) 9 (47.4%)
 2 7 (5.1%) 2 (2.1%) 5 (12.5%) 3 (15.8%)

Smoking Status
 Current 48 (35.3%) 37 (38.5%) 11 (27.5%) 6 (31.6%)
 Former 74 (54.4%) 48 (50.0%) 26 (65.0%) 12 (63.2%)
 Never 14 (10.3%) 11 (11.5%) 3 (7.5%) 1 (5.3%)

Median Pack-years (range) 49 (0-200) 49 (0-200) 40 (0-150) 55 (0-120)

Median FEV1 in Liters (range) 1.98 (0.66-4.31;
n=115)
1.99 (0.74-4.31; n=81) .98 (0.66-3.44; n=34) .98 (0.92-3.44;
n=18)

Tumor Characteristics

Histology:
 Squamous cell carcinoma 29 (21.3%) 19 (19.8%) 10 (25.0%) 5 (26.3%)
 Adenocarcinoma 64 (47.1%) 49 (51.0%) 15 (37.5%) 5 (26.3%)
 Poor differentiated carcinoma 28 (20.6%) 17 (17.7%) 11 (27.5%) 7 (36.8%)
 Small cell lung cancer 15 (11.0%) 11 (11.5%) 4 (10.0%) 2 (10.5%)

T-stage
 0 6 (4.4%) 4 (4.2%) 2 (5.0%) 2 (10.5%)
 1 31 (22.8%) 26 (27.1%) 5 (12.5%) 1 (5.3%)
 2 47 (34.6%) 30 (31.2%) 17 (42.5%) 8 (42.1%)
 3 24 (17.6%) 15 (15.6%) 9 (22.5%) 4 (21.0%)
 4 28 (20.6%) 21 (21.9%) 7 (17.5%) 4 (21.0%)

N-stage
 0 10 (7.4%) 10 (10.4%) 0 (0.0%) 0 (0.0%)
 1 11 (8.1%) 10 (10.4%) 1 (2.5%) 0 (0.0%)
 2 80 (58.8%) 53 (55.2%) 27 (67.5%) 14 (73.7%)
 3 35 (25.7%) 23 (24.0%) 12 (30.0%) 5 (26.3%)

Stage
 IIB 9 (6.6%) 9 (9.4%) 0 (0.0%) 0 (0.0%)
 IIIA 63 (46.3%) 40 (41.7%) 23 (57.5%) 11 (57.9%)
 IIIB 52 (38.2%) 38 (39.6%) 14 (35.0%) 7 (36.8%)
 IV 12 (8.8%) 9 (9.4%) 3 (7.5%) 1 (5.3%)

Treatment Characteristics

Median Radiation Dose (range) 63 Gy (41.4-72.7) 63 Gy (45-72) 66.6 Gy (41.4-72.7) 66.6 Gy (41.4-72.7)

Radiation Technique:
 3D Conformal 34 (25%) 26 (27.1%) 8 (20.0%) 2 (10.5%)
 IMRT 102 (75%) 70 (72.9%) 32 (80.0%) 17 ( 89.5%)

Simulation Technique:
 3D-CT 72 (52.9%) 53 (55.2%) 19 (47.5%) 8 (42.1%)
 4D CT 64 (47.1%) 43 (44.8%) 21 (52.5%) 11 (57.9%)

Radiation Sequencing:
 Pre-operative 15 (11.0%) 13 (13.5%) 2 (5.0%) 0 (0.0%)
 Radiation alone 106 (78.0%) 69 (71.9%) 37 (92.5%) 19 (100%)
 Post-operative 15 (11.0%) 14 (14.6%) 1 (2.5%) 0 (0.0%)

Surgery 30 (22.8%) 27 (28.1%) 3 (7.5%) 0 (0.0%)

Surgery Type
 Wedge 4 (13.3%) 4 (14.8%) 0 -
 Lobectomy 25 (83.3%) 22 (81.5%) 3 (100%) -
 Pneumonectomy 1 (3.3%) 1 (3.7%) 0 -

Any Chemotherapy 130 (95.6%) 91 (94.8%) 39 (97.5%) 18 (94.7%)

Induction Chemotherapy 11 (8.1%) 10 (10.4%) 1 (2.5%) 1 (5.3%)

Concurrent Chemotherapy 121 (89.0%) 82 (85.4%) 39 (97.5%) 18 (94.7%)

Consolidation Chemotherapy 78 (57.4%) 54 (56.3%) 24 (60.0%) 5 (26.3%)

Consolidation Docetaxel 16 (11.8%) 9 (8.3%) 8 (20.0%) 3 (15.8%)

Bilateral Lung Dose-Volume Histogram

 Median V5 (range) 61.7% (21.7-97.2%) 59.4% (21.7-95.0%) 65.3% (38.0 - 97.2%) 63.8% (42.0-97.2%)

 Median V20 (range) 34.0% (9.4-70.0%) 32.4% (9.6-68.7%) 36.3% (21.9-70.0%) 36.4% (22.0-68.0%)

 Median MLD (range) 18.1 Gy (6.1-32.4 Gy) 17.6 Gy (6.1-29.3 Gy) 19.8 Gy (11.0-32.4 Gy) 20.5 (13.3-32.4 Gy)

Includes carcinoma not otherwise specified (NOS) and non-small cell lung cancer NOS.

Abbreviations: CT=computed tomography; FEV1=force expiratory volume in 1 second; IMRT=intensity modulated radiation therapy; MLD=mean lung dose; PS=performance status; V5=volume receiving greater than 5 Gy; V10=volume receiving greater than 10 Gy; V20=volume receiving greater than 20 Gy; RP=radiation pneumonitis.